What is the 13F Pro Quality Score for STAA?

13F Pro ranks STAAR SURGICAL CO (STAA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STAA's current score at https://13fpro.ai/company/STAA (free sign-up required for the full ranking).

Which hedge funds own the most STAA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of STAA include BROADWOOD CAPITAL, BlackRock,, Madison Avenue Partners,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/STAA as soon as new 13F filings post.

Where does 13F Pro source STAA data?

All STAAR SURGICAL CO fundamentals and ownership data come directly from SEC EDGAR. STAAR SURGICAL CO files with the SEC under CIK 718937. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STAA in?

STAAR SURGICAL CO (STAA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STAA research updated on 13F Pro?

STAA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

STAAR SURGICAL CO(STAA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 718937 STAA stock profile & AI dashboard →

13F Pro Quality Score

28.6/100

Rank #2,551 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

20.8/100

Profitability

52.7/100

Balance Sheet

40.4/100

Earnings Quality

17.3/100

Free Cash Flow

23.6/100

Institutional Flow

28.3/100

Revenue Scale

31.5/100

Dilution Risk

13.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why STAA Scores 29/100

exact factor attribution · 2026-09-11

STAA's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+0.4 pts

53th pct

Capital efficiency

-1.0 pts

40th pct

Institutional flow

-1.1 pts

28th pct

Shareholder dilution

-1.8 pts

14th pct

Earnings growth

-2.1 pts

8th pct

Scale

-2.8 pts

32th pct

Earnings quality

-3.3 pts

17th pct

Free cash flow

-4.0 pts

24th pct

Revenue growth

-5.8 pts

21th pct

Latest change (2026-08-12): 18 → 36 · ↑ Profit margin 15→50; ↑ Revenue growth 6→33; despite ↓ Earnings growth 30→4

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in STAA

Events flagged as statistical outliers against STAA's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-12
STAA quality score jumped 18 points (18→36) on a new filing
View source filing →

STAA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for STAAR SURGICAL CO (STAA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STAA at 28.6/100 on a 32-signal composite quality model, placing it at rank #2,551 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (17.3) and revenue growth (20.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), STAAR SURGICAL CO reports quarterly revenue of $93.5M, net income of $8.1M, free cash flow of $19.2M. Top institutional holders of STAA by reported 13-F value include BROADWOOD CAPITAL, BlackRock, Madison Avenue Partners, based on the most recent SEC filings. STAA trades on the Nasdaq exchange and files with the SEC under CIK 718937. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STAA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STAAR SURGICAL CO directly from SEC EDGAR. STAAR SURGICAL CO's 13F Pro composite quality score has ranged between 20 and 65 since 2021, currently 28.6 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about STAAR SURGICAL CO

Quirks, history, and lore behind STAA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue in the range of $300–350 million — not huge, but it commands a premium valuation because its addressable market is enormous and largely untapped.
3
The History
Founded in the 1990s, the company spent years navigating FDA approvals before becoming a niche leader in a corner of ophthalmology that most surgeons rarely touch.
4
The Secret
Its flagship products are implantable lenses placed inside the eye — not on it — making them invisible to the wearer and a genuine alternative to LASIK for certain patients.
5
The Lore
The company is a rare pure-play on implantable collamer lenses (ICLs), and it has increasingly targeted the booming China and India markets where millions of severely myopic patients are underserved.
6
The Giveaway
Its ticker is almost as twinkly as its products: this eye-implant specialist puts tiny lenses inside your eye to fix your vision — and yes, the company name has an extra A in it, just to keep you guessing.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$93.5M

Net Income

Q2 2026

$8.1M

Free Cash Flow

Q2 2026

$19.2M

ROIC

Q2 2026

11.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-23.7% YoY

$239.4MFY 2025

FY22 $239.4MFY23 $322.4MFY24 $313.9MFY25 $239.4M

Net Income

-298.1% YoY

$-80.4MFY 2025

FY22 $39.7MFY23 $21.3MFY24 $-20.2MFY25 $-80.4M

Operating Income

-627.2% YoY

$-91.7MFY 2025

FY22 $43.8MFY23 $28.1MFY24 $-12.6MFY25 $-91.7M

EPS (Diluted)

-295.1% YoY

$-1.62FY 2025

FY22 $0.80FY23 $0.43FY24 $-0.41FY25 $-1.62

Total Assets

-11.4% YoY

$451.7MFY 2025

FY22 $418.8MFY23 $488.7MFY24 $509.5MFY25 $451.7M

Op. Cash Flow

-317.7% YoY

$-34.2MFY 2025

FY22 $35.7MFY23 $14.6MFY24 $15.7MFY25 $-34.2M

Free Cash Flow

-422.2% YoY

$-40.0MFY 2025

FY22 $17.6MFY23 $-3.6MFY24 $-7.7MFY25 $-40.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$239.4M -23.7%	$313.9M -2.6%	$322.4M +34.7%	$239.4M +3.9%	$230.5M +41.0%	$163.5M
Net Income	$-80.4M -298.1%	$-20.2M -194.7%	$21.3M -46.2%	$39.7M +44.2%	$27.5M +365.3%	$5.9M
Operating Income	$-91.7M -627.2%	$-12.6M -144.9%	$28.1M -35.9%	$43.8M +31.4%	$33.3M +392.5%	$6.8M
EPS (Diluted)	$-1.62 -295.1%	$-0.41 -195.3%	$0.43 -46.3%	$0.80 +42.9%	$0.56 +366.7%	$0.12
Total Assets	$451.7M -11.4%	$509.5M +4.3%	$488.7M +16.7%	$418.8M +21.1%	$345.8M +34.3%	$257.4M
Operating Cash Flow	$-34.2M -317.7%	$15.7M +7.7%	$14.6M -59.1%	$35.7M -18.8%	$44.0M +109.8%	$21.0M
Free Cash Flow	$-40.0M -422.2%	$-7.7M -113.4%	$-3.6M -120.4%	$17.6M -41.9%	$30.3M +141.6%	$12.5M

Get alerted when STAA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for STAAR SURGICAL CO including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STAA

BROADWOOD CAPITAL INC
$462.6M16,123,842 sh
BlackRock, Inc.
$193.1M6,731,154 sh
Madison Avenue Partners, LP
$119.8M4,175,748 sh
Yunqi Capital Ltd
$93.4M3,257,130 sh
Point72 Asset Management, L.P.
$69.9M2,437,446 sh
GOLDMAN SACHS GROUP INC
$61.7M2,150,809 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$56.8M1,979,573 sh
STATE STREET CORP
$50.8M1,769,354 sh
Anatole Investment Management Ltd
$47.4M1,651,701 sh
VANGUARD CAPITAL MANAGEMENT LLC
$44.5M1,552,743 sh

Fund	Value	Shares
BROADWOOD CAPITAL INC	$462.6M	16,123,842
BlackRock, Inc.	$193.1M	6,731,154
Madison Avenue Partners, LP	$119.8M	4,175,748
Yunqi Capital Ltd	$93.4M	3,257,130
Point72 Asset Management, L.P.	$69.9M	2,437,446
GOLDMAN SACHS GROUP INC	$61.7M	2,150,809
VANGUARD PORTFOLIO MANAGEMENT LLC	$56.8M	1,979,573
STATE STREET CORP	$50.8M	1,769,354
Anatole Investment Management Ltd	$47.4M	1,651,701
VANGUARD CAPITAL MANAGEMENT LLC	$44.5M	1,552,743

Companies Similar to STAA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

LCTX

Lineage Cell Therapeutics, Inc.

AI score

Similar quality profile · 4 shared holders

BROADWOOD CAPITAL INC Defender Capital, LLC.Williams Jones Wealth Management, LLC.

ANIK

Anika Therapeutics, Inc.

AI score

Similar quality profile · 2 shared holders

Hillsdale Investment Management Inc.OCCUDO QUANTITATIVE STRATEGIES LP

ARVN

ARVINAS, INC.

AI score

Similar quality profile · 4 shared holders

OCCUDO QUANTITATIVE STRATEGIES LP Headlands Technologies LLC Hillsdale Investment Management Inc.

AORT

ARTIVION, INC.

AI score

Similar quality profile · 4 shared holders

DARK FOREST CAPITAL MANAGEMENT LP Colonial Trust Advisors Ankerstar Wealth, LLC

NEOG

NEOGEN CORP

AI score

Similar quality profile · 6 shared holders

Linden Thomas Advisory Services, LLC AMERICAN CAPITAL MANAGEMENT INC FULLER & THALER ASSET MANAGEMENT, INC.

CSTL

CASTLE BIOSCIENCES INC

AI score

Similar quality profile · 1 shared holders

Investors Portfolio Services LLC

AVNS

AVANOS MEDICAL, INC.

AI score

Similar quality profile · 7 shared holders

GABELLI & Co INVESTMENT ADVISERS, INC.MIRABELLA FINANCIAL SERVICES LLP OXFORD ASSET MANAGEMENT LLP

TNDM

TANDEM DIABETES CARE INC

AI score

Similar quality profile · 3 shared holders

DARK FOREST CAPITAL MANAGEMENT LP Ankerstar Wealth, LLC Evolution Advisers, Inc.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STAA on your watchlist

Track score changes the day STAAR SURGICAL CO files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STAA a good stock to buy?

13F Pro's AI-powered analysis of STAAR SURGICAL CO (STAA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STAA are available on the STAA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. STAA is classified as a small company.

Which hedge funds own STAA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STAA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of STAAR SURGICAL CO's investment landscape.